Spindeldreher, Sebastian, Maillère, Bernard, Correia, Evelyne, Tenon, Maxime, Karle, Anette, Jarvis, Philip and Kolbinger, Frank (2018) Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab. Dermatology and therapy, 8 (1). pp. 57-68. ISSN 2193-8210

Abstract

Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy in the treatment of moderate to severe plaque psoriasis (PsO) and psoriatic arthritis (PsA), demonstrating a rapid onset of action and sustained responses with a favorable safety profile. All biotherapeutics, including monoclonal antibodies (mAbs), can be immunogenic, leading to formation of anti-drug antibodies (ADAs) that can result in loss of response and adverse events such as hypersensitivity reactions. Thus, the immunogenicity potential of biotherapeutics is of particular interest for physicians. Of the 2842 patients receiving secukinumab across six phase 3 psoriasis clinical trials, only 0.4% developed treatment-emergent ADAs over 3 years of treatment. Direct comparison of clinical immunogenicity incidence rates is hampered by the nature of clinical immunogenicity assays, differences in study designs, patient populations, and treatment regimens.

Item Type:	Article
Keywords:	Immunogenicity, T cell response, secukinumab, Cosentyx, ixekizumab, Taltz
Date Deposited:	11 Aug 2018 00:45
Last Modified:	11 Aug 2018 00:45
URI:	https://oak.novartis.com/id/eprint/36435